Health Action International (HAI) presents a free, online encyclopaedia of the politics of medicines from the perspective of HAI’s expert network of consumer groups, non-governmental organisations, health care professionals, academics, media and individual partners in more than 70 countries. This is a comprehensive, easy-to-use and accessible resource for a broad audience that is engaged, or interested, in health advocacy, activism, civil society capacity building, or public health outcomes of the medicines market.

What’s Special About This Project?

• Directed at a broad audience
• Provides an up-to-date exploration of the world of medicines and the challenges and controversies it presents to society
• Easily useable and accessible reference source
• Written by experts in the field from HAI’s network for their high level of insight and independence from private interests
  
  

  A

  Are academia–pharma partnerships essential for novel drug discovery in the time of the COVID-19 pandemic?, Joel Lexchin

  ACTA from an Access to Medicines Point of View, Leila Bodeux

  Access to Essential Medicines as a Human Right, Kumariah Balasubramaniam

  Availability, prices and affordability of UN Commission’s lifesaving medicines for reproductive and maternal health in Uganda, Denis Kibira, Freddy Eric Kitutu, Gemma Buckland Merrett & Aukje K. Mantel-Teeuwisse

  Access to sexual and reproductive health commodities in East and Southern Africa: a cross-country comparison of availability, affordability and stock-outs in Kenya, Tanzania, Uganda and Zambia, Ooms, G.I., Kibira, D., Reed, T. et al.

  B

  Barriers to accessing internationally controlled essential medicines in sub-saharan Africa: A scoping review, Gaby I Ooms, Janneke van Oirschot, Denise de Kant, et al.

  Blurring the Boundaries: Conclusion, Barbara Mintzes

  Blurring the Boundaries: Incentives for Drug Sellers, Barbara Mintzes

  Blurring the Boundaries: Introduction, Barbara Mintzes

  Blurring the Boundaries: Promotion Targeting Consumers, Barbara Mintzes

  Blurring the Boundaries: Promotion Targeting Prescribers, Barbara Mintzes

  Blurring the Boundaries: Recommendations, Barbara Mintzes

  Blurring the Boundaries: Research or Promotion?, Barbara Mintzes

  Blurring the Boundaries: The Drug Industry as Health Care Provider, Barbara Mintzes

  Barriers to Accessing Internationally Controlled Essential Medicines in Uganda: A Qualitative Study, Gaby Isabelle Ooms, Paul Klatser, Hendrika A. van den Ham, Tim Reed

  C

  Canada and the pharmaceutical industry in the time of COVID-19, Joel Lexchin

  COVID-19 a litmus test to the fragility of health systems, Denis Kibira

  Can a pharma company change? Profit, not altruism, motivates COVID-19 vaccine development, Joel Lexchin

  Complementary (Traditional & Herbal) Medicines: An Australian Regulatory Perspective, Dr Ken Harvey

  D

  Dependence on Medicines: An Historical Perspective, David Healy

  Disease-mongering, Ray Moynihan

  Drugs for Neglected Diseases initiative; Best Science for the Most Neglected, Eva van Beek and Jean-François Alesandrini

  Donor Commitments and Disbursements for Sexual and Reproductive Health Aid in Kenya, Tanzania, Uganda and Zambia, Denis Kibira et.al

  G

  Generics Competition in the EU, US and Canada, Dr Joel Lexchin

  H

  Health Care Professionals Independent Information About Medicines, Dr Joel Lexchin

  High drug prices in Canada are just one side of a bad equation, Sandra Sirrs and Dr. Joel Lexchin

  I

  Innovation: New Is Not Necessarily Better, Graham Dukes

  International Aid and Access to Health Products, Amit Sengupta

  L

  Learning How Not to Do the Pharmaceutical Industry Tango: Raising Student Awareness of Ethical Conflicts of Interest, Arthur Schafer and Nancy Olivieri

  M

  Mission Sector, Donna Kusemewera

  Models for Financing the Regulation of Pharmaceutical Promotion, Joel Lexchin

  P

  Promotion to Consumers: Responding to Patient Requests for Advertised Medicines, Barbara Mintzes, Les Toop and Dee Mangin

  Promotion, Professional Practice and Patient Trust, Dee Mangin

  Pharmaceutical company responses to Canadian opioid advertising restrictions: A framing analysis, Daniel Eisenkraft Klein, Dr. Joel Lexchin, Abhimanyu Sud and Itai Bavli

  Pharmaceutical Promotion, Barbara Mintzes

  Pharmaceutical R&D, Donald W.Light

  Pharmaceutical Sales Representatives, Andy Gray, Jerome Hoffman and Peter R Mansfield

  Private Health Insurance, Donald W. Light

  Promotion of Medicines and Patient Health, Barbara Mintzes

  Promotion of Medicines in Low- and Middle-Income Countries, Joel Lexchin

  Q

  Quality and quantity of data used by Health Canada in approving new drugs, Dr. Joel Lexchin

  R

  Regulation of Pharmaceutical Promotion: Why Does Regulation Matter?, Lilia Ziganshina and Joel Lexchin

  T

  The Role of Evidence-Based Medicine in Rational Drug Use, Professor K.R. Sethuraman. MD.

  The Medicines Patent Pool, Ellen ‘t Hoen

  The Cochrane Collaboration, Mike Clarke & Phil Wiffen

  The International Network for Rational Use of Drugs (INRUD), John Chalker

  U

  Using Unbiased Prescribing Information, Andy Gray, Bob Goodman, José M. Terán and Barbara Mintzes

  W

  What COVID-19 tells us about prioritisation of health sector financing, Denis Kibira

  WHO Guide to Good Prescribing, Theo P.G.M. de Vries, Milan C. Richir, Jelle Tichelaar

Citing Articles

To cite an article featured on our website, please use the following format:

Author. (Year). Title of article. [Online]. The Politics of Medicines (e-Encyclopaedia). Available at: URL [Accessed on date].

Please note: these articles have not been peer-reviewed.

To submit an article

Email your article to comms@haiweb.org.